¾ÈÁöÀ±(Ahn Jee-Yun) - Seoul National University College of Medicine Seoul National University Bundang Hospital Department of Ophthalmology
À§¿ø·®(Wee Won-Ryang) - Seoul National University College of Medicine Seoul National University Hospital Department of Ophthalmology
ÀÌÁøÇÐ(Lee Jin-Hak) - Seoul National University College of Medicine Seoul National University Bundang Hospital Department of Ophthalmology
ÇöÁØ¿µ(Hyon Joon-Young) - Seoul National University College of Medicine Seoul National University Bundang Hospital Department of Ophthalmology
Abstract
We report a case of vortex keratopathy in a patient treated with vandetanib for non-small cell lung cancer (NSCLC). A 44-year-old female who underwent two cycles of chemotherapy for NSCLC complained of visual blurring in both eyes after the initiation of vandetanib, an anti-epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor receptor 2 protein tyrosine kinase inhibitor. On ophthalmic examination, visual acuities were 20 / 20 OU and, with the exception of diffuse vortex keratopathy in both eyes, other findings were unremarkable. Vandetanib is believed to have caused vortex keratopathy in this patient. Anti-EGFR properties affecting normal corneal epithelial cell migration and wound healing or drug associated metabolite deposition, which is the case in numerous drug-associated vortex keratopathies, may be possible underlying mechanisms in the formation of this corneal complication.
Å°¿öµå
Epidermal growth factor, Vandetanib, Vortex keratopathy
KMID :
0213520110250050355
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
This case demonstrated vortex keratopathy in both eyes while receiving vandetanib for the treatment of NSCLC; This is the first reported domestic case of vandetanib-induced vortex keratopathy.